Latest news and press releases about Aethlon Medical, Inc. (AEMD): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses.
Price
| Price | $1.43 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.09 |
| EV / EBITDA | 0.55 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -123.09% |
| Return on Invested Capital | -127.19% |
| Return on Assets | -111.26% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADAP · ALUR · CODX · ERNA · IINN · LNAI · NVNO
Explore sector: Healthcare · Medical - Devices
More sections of AEMD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks